BioMarin Pharmaceutical Inc. (BMRN)

101.15
0.83 0.83
NASDAQ : Health Technology
Prev Close 100.32
Open 99.99
Day Low/High 99.32 / 101.59
52 Wk Low/High 75.81 / 106.20
Volume 838.68K
Avg Volume 1.24M
Exchange NASDAQ
Shares Outstanding 177.59M
Market Cap 18.08B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioMarin Announces Second Quarter 2018 Results

BioMarin Announces Second Quarter 2018 Results

- Total Revenues of $372.8 million in the Quarter

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

I have not seen a bullish breakout from a large base pattern in a while.

BioMarin Paces a Very Strong Biotech Group

BioMarin Paces a Very Strong Biotech Group

Here's how BMRN's chart looks after its blistering gains.

Chart of the Day: BioMarin Pharmaceutical

BMRN is pacing the very strong biotech group.

BioMarin To Host Second Quarter 2018 Financial Results Conference Call And Webcast On Thursday, August 2 At 4:30pm ET

BioMarin To Host Second Quarter 2018 Financial Results Conference Call And Webcast On Thursday, August 2 At 4:30pm ET

SAN RAFAEL, Calif., July 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Partners With Believe Limited For 'Breaking Through!' Musical Theater Intensive

BioMarin Partners With Believe Limited For 'Breaking Through!' Musical Theater Intensive

First-of-Its-Kind Musical to Help Empower the Bleeding Disorder Community to Find and Use their Voices through the Power of Music

BioMarin Announces First Recipients Of RARE Scholars Scholarship Program

BioMarin Announces First Recipients Of RARE Scholars Scholarship Program

Five Students with Rare Genetic Diseases Receive a Total of $20,000 for Higher Education

BioMarin Doses First Participant In Phase 2 Study Of Vosoritide For Treatment Of Infants And Young Children With Achondroplasia

BioMarin Doses First Participant In Phase 2 Study Of Vosoritide For Treatment Of Infants And Young Children With Achondroplasia

SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Receives Milestone Payments From Pfizer For Talazoparib

BioMarin Receives Milestone Payments From Pfizer For Talazoparib

SAN RAFAEL, Calif., June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

Probing the Long Side of BioMarin

Probing the Long Side of BioMarin

Latest surge boosts chances of breakout in shares of BioMarin.

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

5 Top Stocks With 100% Buy Ratings Right Now

5 Top Stocks With 100% Buy Ratings Right Now

These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.

Why I Stay Very Focused on My Individual Stocks

Why I Stay Very Focused on My Individual Stocks

I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.

Allergan, BioMarin Hold Promise for 2018

Allergan, BioMarin Hold Promise for 2018

The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.

BioMarin Pharmaceutical Stock Sees Short Interest Expand By 10.3%

BioMarin Pharmaceutical Stock Sees Short Interest Expand By 10.3%

The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 842,388 share increase in total short interest for BioMarin Pharmaceutical Inc. , to 9,033,035, an increase of 10.28% since 10/31/2017.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

BioMarin Pharmaceutical: Cramer's Top Takeaways

BioMarin Pharmaceutical: Cramer's Top Takeaways

JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical, gives Jim Cramer an update on the company's drug portfolio.

TheStreet Quant Rating: D+ (Sell)